Literature DB >> 32436265

Genotype-phenotype correlation in children with hereditary spherocytosis.

Soumitra Tole1,2,3, Priya Dhir4, Jakob Pugi1, Luke J Drury5, Sheila Butchart6, Michelle Fantauzzi6, Jacob C Langer7, Jillian M Baker1,4,8, Victor S Blanchette1, Melanie Kirby-Allen1, Manuel D Carcao1,9.   

Abstract

Hereditary spherocytosis (HS) is a common inherited haemolytic anaemia attributed to disturbances in five different red cell membrane proteins. We performed a retrospective study of 166 children with HS and describe the clinical phenotype according to the genotype. In 160/166 (97%) children with HS a disease-causing mutation was identified. Pathogenic variants in ANK1, SPTB, SLC4A1 and SPTA1 were found in 49%, 33%, 13% and 5% of patients. Children with SLC4A1-HS had the mildest phenotype, showing the highest haemoglobin (P < 0·001), lowest reticulocyte counts (P < 0·001) and lowest unconjugated bilirubin levels (P = 0·006), and none required splenectomy in childhood (P < 0·001). Conversely, children with autosomal recessive SPTA1-HS had the most severe clinical phenotype, with almost all patients undergoing splenectomy in early childhood. Patients with ANK1 and SPTB variants showed a similar clinical phenotype. Within each gene, variant type or location did not predict disease severity or likelihood of splenectomy. Among patients with a genetic diagnosis, 47 (29%) underwent splenectomy (23 partial; 24 total) while 57 (36%) underwent cholecystectomy. Total splenectomy led to greater improvements in haemoglobin (P = 0·02). Select use of genetic testing (especially in patients without a family history) may help predict clinical phenotype in childhood and guide family counselling.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  genotype; hereditary spherocytosis; splenectomy

Mesh:

Year:  2020        PMID: 32436265     DOI: 10.1111/bjh.16750

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  A novel SPTB mutation causes hereditary spherocytosis via loss-of-function of β-spectrin.

Authors:  Shan Li; Ping Guo; Leyuan Mi; Xiaojing Chai; Kewang Xi; Ting Liu; Li Lu; Juan Li
Journal:  Ann Hematol       Date:  2022-01-31       Impact factor: 3.673

2.  Analysis of MRI-derived spleen iron in the UK Biobank identifies genetic variation linked to iron homeostasis and hemolysis.

Authors:  Elena P Sorokin; Nicolas Basty; Brandon Whitcher; Yi Liu; Jimmy D Bell; Robert L Cohen; Madeleine Cule; E Louise Thomas
Journal:  Am J Hum Genet       Date:  2022-05-13       Impact factor: 11.043

3.  Facilitating EMA binding test performance using fluorescent beads combined with next-generation sequencing.

Authors:  Andreas Glenthøj; Christian Brieghel; Amina Nardo-Marino; Richard van Wijk; Henrik Birgens; Jesper Petersen
Journal:  EJHaem       Date:  2021-09-09

4.  Preliminary Study on the Clinical and Genetic Characteristics of Hereditary Spherocytosis in 15 Chinese Children.

Authors:  Chongjun Wu; Ting Xiong; Zhongjin Xu; Chunlei Zhan; Feng Chen; Yao Ye; Hong Wang; Yu Yang
Journal:  Front Genet       Date:  2021-03-18       Impact factor: 4.599

5.  Clinical and genetic diagnosis of thirteen Japanese patients with hereditary spherocytosis.

Authors:  Keiko Shimojima Yamamoto; Taiju Utshigisawa; Hiromi Ogura; Takako Aoki; Takahiro Kawakami; Shoichi Ohga; Akira Ohara; Etsuro Ito; Toshiyuki Yamamoto; Hitoshi Kanno
Journal:  Hum Genome Var       Date:  2022-01-12

6.  Identification of a Novel Mutation of β-Spectrin in Hereditary Spherocytosis Using Whole Exome Sequencing.

Authors:  Dżamila M Bogusławska; Michał Skulski; Beata Machnicka; Stanisław Potoczek; Sebastian Kraszewski; Kazimierz Kuliczkowski; Aleksander F Sikorski
Journal:  Int J Mol Sci       Date:  2021-10-12       Impact factor: 5.923

7.  Identification of proteomic markers for prediction of the response to 5-Fluorouracil based neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.

Authors:  Jianan Wang; Jiayu Liu; Jinyang Wang; Shijian Wang; Feifei Li; Ruibing Li; Peng Liu; Mianyang Li; Chengbin Wang
Journal:  Cancer Cell Int       Date:  2022-03-15       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.